News

Epstein-Barr: New Therapeutic Target in SLE?


 

“If you accept the idea that the virus is a necessary condition in order to develop lupus—just hypothetically—then if a way was developed to rid the body of the virus and the virus' presence was needed to sustain the disease, then that would be a new therapeutic approach. The virus has been adapted to human beings for something like 20 million years. So it has found a wonderful niche in our peculiar environment, and it has many presumably unknown ways of sustaining that infection,” he said.

Disclosures: Dr. Harley disclosed that he is on the board of directors of IVAX Diagnostics Inc., and JK Autoimmunity Inc. He is also a consultant to UCB and Bio-Rad Laboratories Inc.

Serum from the DOD repository showed increased anti-EBV titers in patients years before they developed SLE.

Source DR. HARLEY

Pages

Recommended Reading

CVD May Be Linked to Depression in Lupus
MDedge Rheumatology
Bosentan May Reduce Sclerotic Skin Fibrosis
MDedge Rheumatology
Clonal T Cells Role Held Key In Scleroderma
MDedge Rheumatology
Index Measures Partial Improvement in SLE
MDedge Rheumatology
Delaying Ambrisentan Cuts Long-Term Lung Capacity
MDedge Rheumatology
Oral Imatinib Shows Promise for Pulmonary Arterial Hypertension
MDedge Rheumatology
Vasoreactivity Testing a Must in Idiopathic PAH : Oral calcium channel blockers have no place in this testing, warns an ACC/AHA consensus statement.
MDedge Rheumatology
Clinically Quiescent Lupus Does Not Progress
MDedge Rheumatology
ACP Report: Support Family Caregivers
MDedge Rheumatology
Hallucinations Common in Pediatric Lupus
MDedge Rheumatology